downgrad under-perform limit
upsid late-stag lc product cycl
downgrad u/p organ growth continu lag
downgrad water under-perform neutral lower po
see continu softer perform think target
organ sale growth may ambiti downgrad base larg
deceler liquid chromatographi lc product cycl concern share shift
market wat slow start year core growth sinc
peak pharma lc product upgrad cycl wat core revenu growth
deceler model
addit believ along diversifi busi
presenc industri food academ end market well pharma
sale compani face increas level competit also biolog becom
greater part market trend work drug like less
profit compani qa/qc qualiti assurance/qu control vs small
molecul believ dynam take time play downgrad
call think lower organ growth profil lead stock
under-perform rel lst life scienc tool peer group
share buyback key upsid risk earn growth
note signific potenti boost earn via share buyback
post-u tax reform easier access ou cash cash
short-term invest balanc sheet abil buy-back
outstand share author next yr model
time period aggress buy-back could add roughli
eps/yr yoy key upsid risk est think
outweigh organ growth stori focu lst investor
new po ep line w/ histor average
trim est see adj ep vs prior
new po base ep previous ep
line compani histor averag peer-group
trade price-to-earnings upsid risk higher level share buyback better core
growth acquisit compani downsid risk slower core growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
water face difficult market condit
product cycl share shift market
expect continu soft perform
view target ambiti believ
dynam take time play
share buyback may off-set earn
soft expect slower organ growth
lead under-perform rel peer
po base dcf analysi assum wacc
termin growth impli pe multipl estim
in-lin histor trade level past year believ multipl
justifi given current growth profil peer-group valuat
slow china tariff/trad war escal weaker global economi share
loss competitor slowdown pharma biotech spend downsid
risk price object upsid risk po aggress capit
deploy faster expect uptak new product acquisit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
